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Metformin and glucose starvation 
decrease the migratory ability of 
hepatocellular carcinoma cells: 
targeting AMpK activation to 
control migration
Anabela C. Ferretti, Florencia Hidalgo, Facundo M. tonucci, evangelina Almada, 
Alejandro pariani, María C. Larocca & Cristián Favre
Hepatocellular carcinoma (HCC) is a highly metastatic cancer with very poor prognosis. AMp activated 
kinase (AMpK) constitutes a candidate to inhibit HCC progression. First, AMpK is downregulated in 
HCC. second, glucose starvation induces apoptosis in HCC cells via AMpK. Correspondingly, metformin 
activates AMPK and inhibits HCC cell proliferation. Nevertheless, the effect of AMPK activation on 
HCC cell invasiveness remains elusive. Here, migration/invasion was studied in HCC cells exposed to 
metformin and glucose starvation. Cell viability, proliferation and differentiation, as well as AMPK 
and pKA activation were analyzed. In addition, invasiveness in mutants of the AMpKα activation loop 
was assessed. Metformin decreased cell migration, invasion and epithelial-mesenchymal transition, 
and interference with AMpKα expression avoided metformin actions. Those antitumor effects were 
potentiated by glucose deprivation. Metformin activated AMpK at the same time that inhibited pKA, 
and both effects were enhanced by glucose starvation. Given that AMPKα(S173) phosphorylation 
by PKA decreases AMPK activation, we hypothesized that the reduction of PKA inhibitory effect by 
metformin could explain the increased antitumor effects observed. Supporting this, in AMPK activating 
conditions, cell migration/invasion was further impaired in AMpKα(S173C) mutant cells. Metformin 
emerges as a strong inhibitor of migration/invasion in HCC cells, and glucose restriction potentiates this 
effect.
Hepatocellular carcinoma (HCC) is a rather frequent and much more aggressive cancer, mainly due to its feature 
of developing intra and extrahepatic metastasis at an extremely rapid rate1. Accumulation of genetic and microen-
viromental changes take place in hepatocytes during chronic inflammation associated to a basal liver disease in 
90% of HCC patients, and this scenario promotes malignant transformation from early dysplastic to multiple and 
genetically-heterogeneous nodules2. Despite administration of surgical or current pharmacological treatment, 
most people diagnosed with HCC die within two years of being diagnosed, and this statistics positions HCC as 
the second cause of cancer death worldwide2,3. Elucidation of the mechanisms controlling cell proliferation and, 
specially, migration constitutes a main issue for understanding the bases of the disease and hence for foreseeing 
therapeutic strategies to limit its development.
In the last years, AMP activated kinase (AMPK) signaling was demonstrated to be involved in HCC eti-
ology and has become a promising therapeutic target4–7. In fact, AMPK activity is significantly decreased in 
tumor compared with non-tumor region, and this downregulation is associated with worst HCC prognoses4,6. 
AMPK consists of a heterotrimer of catalytic (α), regulatory (β), and activation (γ) subunits, which response to 
energy stress in most tissues and cell types. Upon activation, AMPK enhances fatty acids and glucose oxidation 
and inhibits protein biogenesis thus leading to the restitution of ATP levels8. In addition, AMPK signals cell 
cycle arrest and survival regulation in tumor cells9–11. Moreover, even when it has not been as well characterized, 
institute of experimental Physiology, cOnicet, School of Biochemical Sciences, University of Rosario, Rosario, 
Argentina. Anabela c. ferretti and florencia Hidalgo contributed equally. correspondence and requests for materials 
should be addressed to c.f. (email: favre@ifise-conicet.gov.ar)
Received: 20 July 2018
Accepted: 17 January 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:2815  | https://doi.org/10.1038/s41598-019-39556-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
C3A HuH-7
































































































































































































































Figure 1. Metformin, from low concentrations, inhibits migration in HCC cells. (a) HCC cells were incubated 
for 24 h in complete DMEM alone (C), or in the presence of 1–20 mM metformin (M), and cell number 
was evaluated by MTT assay. Bars represent the mean cell viability expressed as percentage of C ± SEM of 4 
independent experiments. (b) HCC cells were incubated for 24 or 48 h in complete DMEM alone (C), or in 
the presence of 1 (M1) or 5 mM (M5) metformin and cell proliferation was evaluated by BrdU incorporation 
assay. Bar represents the mean percentage of positive nuclei counted ± SEM. The assay was evaluated for 3 
independent experiments (c) HepG2/C3A cells were incubated with complete DMEM (C), or in the presence 
of 1 (M1) or 5 mM (M5) metformin. P-AMPKα(T172) and AMPKα protein levels were detected in cell lysates 
after 24 h. α Tubulin was used as loading control. Selected lanes for each detection are in their original order and 
correspond to the same gel, and they are shown after cropping, aligning and separating them by white space. 
Full-length blots are available in Supplementary Dataset. Immunoblots show an experiment representative of 
3 independent experiments. Bars represent P-AMPKα band densities relative to the corresponding α Tubulin 
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AMPK activation can also affect cell motility and hence it can decrease the metastatic capacity of cancer cells12–14. 
We have recently demonstrated that AMPK is the key kinase pathway that controls cell death in HCC cells under-
going glucose restriction: AMPKα silencing in HCC cells prevents both cell cycle arrest and apoptosis induced 
by glucose starvation15. However, scanty information exists regarding the involvement of AMPK signaling in 
HCC cell migration. Besides the allosteric effect of AMP, activation of AMPK during nutritional stress requires 
phosphorylation of Thr172 residue of AMPKα by LKB18. AMPK activation can be negatively regulated by phos-
phorylation of different regulatory residues by PKA and/or AKT16–18. Our previous findings indicated that Ser173 
phosphorylation by PKA reduces phospho-AMPKα(T172) levels and prevents apoptotic activation in HCC cells 
subjected to nutritional stress15.
Metformin, an antidiabetogenic drug which in recent years has entered into the limelight of promising anti-
cancer drugs19, is a bonafide AMPK activator. Metformin activates AMPK via affecting mitochondrial respiration 
complex I and AMP/ATP ratio20, as well as by favoring LKB1 activation21,22. Furthermore, it has been shown 
that metformin can also indirectly activate AMPK by inhibiting PKA and therefore decreasing AMPKα(S173) 
phosphorylation23. Recent studies showed that metformin diminishes proliferation in HCC cells in vitro or in 
xenotransplanted nude mice4. Because of its antiproliferative effects, metformin is nowadays being studied for 
cancer therapy in diverse clinical trials. Nevertheless, AMPK participation in the regulation of HCC cell migra-
tion and metformin putative actions on this pathway remain elusive.
We hypothesize that AMPK signaling can inhibit HCC cell migration and that the extent of this effect depends 
on AMPK activation effectiveness in each cellular context. In this study, we aimed to analyze migratory capacity 
in HCC derived cells treated with metformin and combined with glucose starvation condition. We presented 
strong evidence supporting that metformin exerted a considerable antimigratory effect in HCC cells which was 
potentiated by glucose restriction. Results on the migratory response of HCC cells with non phosphorylatable 
mutation of S173 residue of AMPKα were also analyzed.
Results
Metformin decreases migration in two HCC cell lines with different migratory behavior. 
HepG2/C3A and HuH-7 cell number after 24 h metformin incubation at a rank of concentrations most frequently 
used for cancer cell treatment was screened by MTT assay (Fig. 1a). Remarkably, 1 and 5 mM metformin led to 
mild (15–30%) decreases in total viable cells. The higher concentrations of 10 and 20 mM led to decreases in 
cell number which surpassed 50%. Proliferation rates in both cell lines subjected to metformin treatment at the 
lower concentrations were evaluated by BrdU incorporation assay: After 24 h treatment neither 1 mM nor 5 mM 
metformin induced any significant change in BrdU incorporation. On the other hand, after 48 h treatment, 1 mM 
metformin showed only a tendency to elicit an antiproliferative effect, although 5 mM metformin significantly 
decreased the number of positive nuclei (Fig. 1b).
In turn, the effect of metformin at these lower concentrations on 2D cell migration was evaluated by wound 
healing assays. The effects of two different AMPK activating conditions, AICAR and glucose deprivation, were 
also analyzed and compared using the same assay (Fig. 1d). Metformin significantly inhibited cell migration in 
a dose dependent manner in HepG2/C3A and HuH-7 cells (Fig. 1d). This effect was similar in both cell lines, 
regardless of their different migratory efficiencies, and it was in accordance with the extent in AMPK activation, 
which was mild with 1 mM metformin (+77%) and greater with 5 mM metformin (+228%) (Fig. 1c). In fact, the 
distance advanced by the cells 24 h after wounding was reduced by around 30% or 60% of the control group when 
cells were treated with metformin at 1 or 5 mM, respectively (Fig. 1d). The velocity of migration of individual cells 
in the wound front was also estimated by time-lapse studies. These results see Supplementary Fig. 1 corroborated 
that the effect of metformin on the migratory function detected by wound healing assay as a global measure of 
collective migration was similar to that observed by single-cell tracking.
Taking together, these results suggested that AMPK activation entailed antimigratory effects in HCC cells, 
and that 1 mM metformin was already effective in inhibiting the cell migratory ability, whilst only subtly induced 
citotoxicity.
Metformin effects on transwell migration/invasion assay in HCC cells. To further characterize the 
effects on cell migration/invasion, we performed a 3D cell migration/invasion assay by analyzing the ability of 
cells to migrate through a matrigel coated membrane. Figure 2a depicts typical captures of matrigel coated tran-
swells after the different treatments. Cell invasiveness decreased, approximately, to 40 and 60% of control levels 
in C3A and HuH-7 cells, respectively, when treated with 1 mM metformin, and to 20% in the presence of 5 mM 
metformin (Fig. 2b). Collectively, these results showed that metformin was a potent inhibitor of migration/inva-
sion in HCC derived cells.
Silencing of AMPK suppresses metformin antimigratory and anti-invasive effects. The expres-
sion of AMPKα was diminished with specific siRNAs (AMPK KD) in HepG2/C3A and HuH-7 cells (Fig. 2c). 
Phosphorylation of AMPKα (Thr172) and ACC(Ser78/80) was detected in AMPKα silenced cells with or without 
band densities and are expressed as % of the control. *P < 0.05 vs. C, #P < 0.05 vs. M1. (d) Confluent HCC cells 
were subjected to scratch wounding (0 h) and incubated in complete DMEM alone (C), or in the presence of 
1 (M1) or 5 mM (M5) metformin, or 1 mM AICAR (AICAR), or glucose starved by incubation in no-glucose 
DMEM (GS). Images illustrate wound gaps at 0 h and 24 h. Bars represent the mean distance migrated by 
the “wound front”. Values represent the mean ± SEM from 18 fields for an experiment representative of 3 
independent experiments. *P < 0.05 vs. C.
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Figure 2. Metformin decreases invasiveness in HCC cells and AMPK knock down blocks metformin inhibition 
of cell migration/invasion. HCC cells were plated onto the upper compartment of Matrigel-coated filters of 
transwell chambers and incubated with complete DMEM alone (C) or in the presence of 1 (M1) or 5 mM (M5) 
metformin. After 48 h, cells that had migrated to the bottom of the filter were stained using toluidine blue, 
photographed and quantified. (a) Representatives images of cells that invaded the lower chamber are shown. (b) 
Quantitative data are shown as percentages of C. Bars indicate the mean ± SEM of 3 independent experiments. 
(c) HCC cells were transfected with AMPKα1 targeted (AMPK KD), or scrambled (Control) siRNAs. AMPKα 
expression was analyzed 72 h post-transfection by immunoblotting in Control and AMPK KD C3A and HuH-7 
cells. α Tubulin was used as loading control. Selected lanes for each detection are in their original order and 
correspond to the same gel, and they are shown after cropping, aligning and separating them by white space. 
Full-length blots are presented in Supplementary Dataset. Immunoblots show an experiment representative of 3 
independent experiments. (d) HepG2/C3A cells were transfected with AMPKα1 targeted or scrambled siRNAs 
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1 mM metformin in order to corroborate the involvement of AMPK signaling. We found that metformin-induced 
phosphorylations of AMPKα and ACC were abrogated in AMPK KD cells (Fig. 2d).
In addition, given that during energetic stress p53 status in hepatic cells seems to be tightly regulated by 
AMPK activity24, together with the fact that we previously observed increases of the p53 transactivated proteins 
p21 and Puma after AMPK activation by glucose starvation in HCC cells15, we decided to evaluate p53 levels in 
control and AMPK silenced HCC cells treated with metformin. Metformin entailed an augment of total p53 and 
this putative stabilization was dependent on AMPK. In fact, negligible amounts of p53 were observed in AMPK 
KD cells (Fig. 2d).
Migration and invasion assays were performed in control and AMPK KD cells in the presence of metformin. 
The interference of AMPKα expression abrogated the inhibition of migration (Fig. 2e) and invasion (Fig. 2f) 
elicited by 1 mM metformin in HCC cells. Besides, migration studies carried out in the p53-null cell line Hep3B 
demonstrated no inhibitory effects of metformin See Supplementary Fig. 2. These results suggested that an intact 
AMPK-p53 axis was necessary to observe the antimigratory effects of metformin in HCC cells.
Metformin promotes acquisition of differentiated epithelial phenotype. Expression of epithelial 
and mesenchymal markers was evaluated. E-cadherin levels were significantly increased whilst vimentin levels 
were significantly decreased after being treated with metformin, at 1 or 5 mM, for 24 h (Fig. 3a). In spite of their 
tumor origin, HepG2/C3A cells can develop pseudocanaliculi, which resemble the epithelial structures typical 
of differentiated hepatocytes25. Considering that cell migration depends on changes in polarity associated to loss 
of epithelial features, cell differentiation was evaluated as the extent of formation of pseudocanaliculi in HepG2/
C3A cells. In accordance with its antimigratory effect, 1 mM metformin increased the number of these canalicular 
structures in HCC cells (Fig. 3b). In association with this increase in differentiation, E-cadherin protein levels in 
these cells kept significantly augmented after 72 h treatment with 1 mM metformin (Fig. 3b). Altogether, these 
results indicated that metformin inhibited epithelial-mesenchymal transition (EMT) in HCC cells.
Combination of metformin and glucose deprivation enhanced the inhibition of HCC cell migra-
tion and invasion. In a previous work, we demonstrated that AMPK is the central kinase controlling apop-
totic activation in HCC cells undergoing glucose starvation. In fact, AMPK activation after glucose deprivation 
is rapid and marked and its silencing completely blocks the augment in the apoptotic population induced by 
glucose deprivation15. Nevertheless, there is no data available regarding the putative effect of this activation on 
cell migration. Metformin is a well-known antiproliferative and cytotoxic drug, either alone or in combination 
with another antitumor treatment in diverse cells26–28. In HCC derived cells metformin (5 to 10 mM) leads to cell 
cycle arrest4,23,29, and apoptosis30. Therefore, we studied if any additive or synergic effect on cell cycle or death, 
and, more intriguing, on cell migration could be produce by combination of glucose restriction and metformin 
treatment in HCC cells.
Our results showed that 1 mM metformin was not enough to produce cell cycle arrest after 48 h of treatment 
(Fig. 4a). However, the same treatment conditions significantly increased total apoptosis to almost 30% of the 
whole cell population (Fig. 4b). In addition, and in accordance with the literature, 5 mM metformin did achieve 
both significant cell cycle arrest (Fig. 4a and Supplementary Fig. 3), and apoptotic activation (Fig. 4b). When C3A 
cells were incubated with 5 mM metformin in a glucose starving condition, the percentage of apoptotic cells was 
significantly enhanced from 52 to 72% (Fig. 4b), whereas the percentage of non-apoptotic viable cells decreased 
to 18%. For this reason, cell cycle distribution was not analyzed in this group of cells. These results showed that 
there was a dose dependent effect of metformin on apoptotic activation which was much more prominent in 
conditions of nutritional stress.
Once these effects on cell cycle and apoptosis were characterized, the effect of combination of 1 mM met-
formin with glucose deprivation on migration and invasion in HCC cells was analyzed. In C3A cells, glucose 
starvation doubled the inhibition of migration induced by 1 mM metformin in control conditions: from −27% 
to −53% (Fig. 4c). Similar results were obtained for HuH-7 cells see Supplementary Fig. 3. In the same direction, 
1 mM metformin combined with glucose deprivation prompted a marked inhibition of invasion in C3A cells 
when compared to metformin alone: from −48% to −75% (Fig. 4d).
Total viability of glucose starved C3A and HuH-7 cells treated with 5 mM metformin for 24 h decreased to 
almost 65 and 40% of control levels, respectively see Supplementary Fig. 4. Therefore, the effects of treatment 
combination on cell migration and invasiveness could not be evaluated for 5 mM metformin, because 24 and 48 h 
assays were required.
and cultured for 48 h, after then additional 24 h treatment with or without 1 mM metformin was performed. 
P-AMPKα(T172), AMPKα, P-ACC, ACC and p53 were detected by immunoblotting. α Tubulin was used as 
loading control. Selected lanes for each detection are in their original order and correspond to the same gel, 
and they are shown after cropping, aligning and separating them by white space. Full-length blots are presented 
in Supplementary Dataset. Immunoblots show an experiment representative of 3 independent experiments. 
(e) 48 h post-transfection AMPK KD and Control HuH-7 cells were subjected to scratch wounding (0 h) and 
incubated with complete DMEM alone (C), or in the presence of 1 mM metformin (M1) for 24 h. Data were 
obtained as indicated in Fig. 1b. (f) 24 h post-transfection AMPK KD and Control C3A cells were plated in 
transwell chambers as detailed in a and incubated with complete DMEM alone (C), or in the presence of 1 mM 
metformin (M1) for 48 h, and processed as indicated in a. *P < 0.05 vs. C.
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pKA and AMpK signaling in HCC cells exposed to metformin and glucose deprivation. Besides 
its role as an AMPK activator, there is evidence that metformin also acts as a PKA inhibitor in hepatic cells23. 
Therefore, we explored if the increase in the antitumor effects of metformin induced by glucose starvation were 
associated to changes in the activities of these signaling kinases. As a first approach, we analyzed AMPK and PKA 
activation, by detecting P-AMPKα(T172) and phosphorylation of PKA substrates in HCC cells cultured in the 
presence of 1 and 5 mM metformin (Fig. 5a). Metformin treatment increased AMPK activation in a dose depend-
ent manner, and decreased PKA activation at 5 mM. When combined treatment of glucose restriction plus 5 mM 
metformin was analyzed, we observed that PKA activity was almost undetectable, and activation of AMPK was 
significantly enhanced (Fig. 5b). This hyper-activation of AMPK paralleled the increase in apoptosis observed by 
Annexin V/IP assays in the 5 mM metformin plus glucose starvation setting.
It is noteworthy that 1 mM metformin plus glucose starvation did not increase P-AMPKα(T172) levels above 
those levels elicited by single treatments see Supplementary Fig. 5. In this regard, cell cycle and cell death analysis 
also showed that combination of 1 mM metformin with glucose withdrawal have no additive effects, what, col-
lectively, indicated that apoptotic death levels correlated with the extent of AMPK activation. However, the same 
combination of treatments did intensify the inhibition of HCC cell migration/invasion, what could be probably 
due to additional effects of glucose restriction on these functions which were, at least in part, independent of 
further AMPK activation.
Subsequently, we focused on the negative regulation of AMPK by PKA in HCC cells. We have previously 
described that cell death induced by glucose withdrawal in HCC cells is conditioned by PKA inhibition of 
AMPK15 A set of experiments was performed to evaluate migration in the presence of the specifically designed 
peptide inhibitor of PKA (PKI) (Fig. 5c), 1 mM metformin, or both. Results showed that PKA participated in 
regulating migration in HCC cells and demonstrated additive effects of PKA inhibition and 1 mM metformin 
in reducing HCC cell migration (Fig. 5d). Similar data were obtained by using H89 plus 1 mM metformin (data 
nor shown). We pondered if this axis also affected glucose starvation effects on cell migration. Therefore, we 
evaluated the effect of the PKA inhibitor H89 on the migratory capacity of control and glucose starved cells. In 
line with our previous results, inhibition of PKA by H89 reinforced the reduction in the efficiency of C3A cell 
migration observed during glucose starvation see Supplementary Fig. 6b, and this was associated to the fact that 
H89 increased AMPK activation in glucose-fasted cells see Supplementary Fig. 6a. Similar results were obtained 
for HuH-7 cells (data not shown).
All together, these findings supported the hypothesis that PKA counteracted AMPK activation and that higher 
levels of AMPK activation were achieved in HCC cells when PKA was inhibited by metformin (Fig. 5e).
Contribution of AMpKα Ser173 site to cell migration. We demonstrated that the simultaneous treat-
ment of HCC cells with 5 mM metformin and glucose restriction increased AMPK activation, which was con-
comitant with a decrease of PKA activation. In this connection, a study focused on the response to glucagon in 
liver cells, showed that metformin inhibits PKA and, concurrently, the specific phosphorylation of AMPKα(S173) 
by PKA23. Our own previous results in HCC cells pointed that mutation of AMPKα(S173) to the non phospho-











































Figure 3. Metformin favors the acquisition of a differentiated epithelial phenotype in association with 
increased E-cadherin and reduced vimentin levels. (a) C3A and HuH-7 cells were incubated in complete 
DMEM alone (C) or in the presence of 1 mM (M1) or 5 mM (M5) metformin for 24 h and E-cadherin and 
vimentin were detected in cell lysates. α Tubulin was used as loading control. Selected lanes for each detection 
are in their original order and correspond to the same gel, and they are shown after cropping, aligning and 
separating them by white space. Full-length blots are available in Supplementary Dataset. Immunoblots 
show an experiment representative of 3 independent experiments. (b) C3A cells were incubated for 72 h in 
complete DMEM alone (C) or in the presence of 1 mM metformin (M1). Afterwards, cells were fixed and 
stained to visualize actin cytoskeleton and nuclei, and canalicular structures were quantified. Arrows indicate 
representative canaliculi. Bars represent the mean number of canaliculi per 100 cells. Values represent the 
mean ± SEM from 10 fields for an experiment representative of 3 independent experiments. Below, E-cadherin 
was detected in the corresponding cell lysates from each experimental group. α Tubulin was used as loading 
control. Immunoblots show an experiment representative of 3 independent experiments. *P < 0.05 vs. C.
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apoptotic death15. In the present work, we corroborated that AMPK activation occurred in WT and S173C mutant 
cells treated with 1 or 5 mM metformin. However, when subjected to 1 mM metformin the mutant clone showed 
greater induction of T172 phosphorylation. Concomitantly, both in basal and 1mM-metformin conditions, the 
levels of the epithelial marker E-cadherin were higher in the S173C mutant (Fig. 6a). This indicated that the lack 
of phosphorylation of S173 (by PKA) favored AMPK activation and hence increased epithelial differentiation. 
Taking together these results, we hypothesized that the phosphorylation state of this site could modulate AMPK 
signaling in HCC cells migratory function. To address this hypothesis, wound healing and transwell migration 
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Figure 4. Combination of metformin and glucose deprivation on cell cycle, cell death, migration and invasion. 
C3A cells were incubated with complete DMEM (C), or glucose starved by incubation in no-glucose DMEM 
(GS), with or without 1 (M1) or 5 mM (M5) metformin for 48 h. (a) Cells were fixed, stained with propidium 
iodide, and their distribution in cell cycle was analyzed by flow cytometry. Bar charts show the percentage of 
cells in G0/G1 and S phases. (b) Cells were stained for AnnexinV/IP assay and the percentages of apoptotic cells 
were determined by flow cytometry analysis. Bar represent the total percentages of apopotic cells (Annexin V 
positive). Values are the mean ± SEM of 3 (cell cycle) or 4 (AnnexinV/IP) independent experiments. (c) C3A 
cells were subjected to scratch wounding (0 h) and incubated with complete DMEM (C), or subjected to glucose 
starvation (GS), with or without 1 mM metformin (M1) for 24 h. Data were obtained as indicated in Fig. 1b. 
(d) C3A cells were plated in transwell chambers as detailed in Fig. 2 and incubated with complete DMEM (C), 
or glucose starved (GS), with or without 1 mM metformin (M1) for 48 h, and processed as indicated in Fig. 2. 
*P < 0.05 vs. C. aP < 0.05 vs. GS. bP < 0.05 vs. M5 (b) or M1 (c,d).
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assays were performed in HCC cells harboring non phosphorylatable mutation of the S173 phosphorylation site. 
In every AMPK activating conditions assessed, migration of AMPKα(S173C) cells was significantly decreased 
when compared to AMPKαWT cells (Fig. 6b). Besides, when cells were incubated with the concentration of 
metformin that inhibited PKA (5 mM) the mutation became ineffective (Fig. 6b), which was in accordance with 
the similar levels of E-cadherin (and activated AMPK) reached in mutant and wild type cells treated with this 
concentration of metformin (Fig. 6a).
Comparable results were obtained in invasion assays, where, after glucose withdrawal, or incubation with 
metformin or AICAR, cell invasiveness was significantly decreased in AMPKα(S173C) compared to AMPKαWT 
cells. As a sake of example, inhibition of invasion increased from 48 to 83% in WT and mutant cells incubated 
with 1 mM metformin, respectively (Fig. 6c). Summarizing, these results demonstrated that cells harboring an 
AMPK mutant form that is not inhibitable by PKA had diminished migration and invasion abilities.
Discussion
EMT is a continuous matter of study in liver cancer due to the presence of fibrosis in the underlying liver disease 
which, coupled with other special features of the hepatocytes, point to EMT regulation as a target for the control 
of HCC development31. It is well known that AMPK signals epithelial differentiation in primary cultured hepato-
cytes. Moreover, activation of AMPK by metformin significantly increases epithelial cell polarity in normal hepat-
ocytes32. However, the putative AMPK role in the regulation of cell migration process during HCC progression 
remains unexplored. Here, we aimed to study the effect of AMPK activation on migration and invasion in HCC 
derived cells and, specifically, when they were treated with the emergent anticarcinogen metformin.
C M1
α Tubulin
M5 C M1 M5
C3A HuH-7

















































Figure 5. Effect of metformin on PKA/AMPK signaling in glucose fed and glucose fasted cells. (a,b) HCC 
cells were incubated with complete DMEM (C), or glucose starved by incubation in no-glucose DMEM (GS), 
with or without 1 (M1) or 5 mM (M5) metformin for 24 h. Protein levels of P-AMPKα(T172), AMPKα, and 
phosphorylated PKA substrates were detected. α Tubulin was used as loading control. The bands of PKA 
substrates which were modified are indicated with arrow heads in the first blot of C3A cells. Full-length blots 
are available in Supplementary Dataset. Immunoblots show an experiment representative of 3 independent 
experiments. (c) C3A cells were incubated with complete DMEM (C), with or without 10 μM PKI (PKI) for 
24 h and phosphorylated PKA substrates were detected in cell lysates. α Tubulin was used as loading control. 
Selected lanes for each detection are in their original order and correspond to the same gel, and they are shown 
after cropping, aligning and separating them by white space. Full-length blots are available in Supplementary 
Dataset. Immunoblots show an experiment representative of 3 independent experiments. (d) C3A cells were 
incubated with complete DMEM (C), in the presence of 1 mM metformin (M1), 10 μM PKI (PKI) or both 
(PKI M1) for 24 h. Cells were subjected to scratch wounding (0 h) and cell migration was assessed after 24 h, 
as indicated in Fig. 1d. Bars represent the mean distance migrated by the “wound front” expressed as % of the 
distance advanced in the control group. Values represent the mean ± SEM from 8–14 fields for an experiment 
representative of 3 independent experiments. *P < 0.05 vs. C. #P < 0.05 vs. M1. (e) Proposed model for AMPK 
activation by PKA inhibitors (metformin, PKI or H89) which entail reduction of HCC cell migration. Glucose 
starvation also activates AMPK, and under this condition inhibition of migration is reinforced. Mechanisms not 
yet clarified independent of AMPK activation could also decrease cell migration (dashed line). *P < 0.05 vs. C. 
#P < 0.05 vs. GS.
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Metformin biological mechanisms and their impacts seem very diverse, and further basic and clinical studies 
are necessary to understand the complete picture of its antitumor actions32,33. In diabetes treatment, metformin 
has many benefits and a safety dosage, and it became the most useful oral hypoglycemiant34. Interestingly, val-
uable metformin results in patients supporting its possible role as anticarcinogen come from the reduction of 
cancer frequencies in diabetic patients35. Moreover, HCC is prevented in metformin treated patients36,37, which 
is more significant considering that diabetes is a risk factor for HCC2. Metformin concentrates in the liver due to 
the enrichment of the transport protein OCT1 in hepatic cells, which also transports cations as sorafenib38. Taken 
together, this background makes HCC a unique candidate for metformin studies.
First, we showed that a concentration of metformin that causes still meager or no effect on cell cycle and 
death, does induce significant inhibition of cell migration and invasion in two HCC derived cell lines with dif-
ferent migratory efficiencies. Additionally, either the AMP analog AICAR or glucose starvation induced similar 
reduction of migration. In turn, we found that metformin inhibitory effects on migration and invasion were 
c









Figure 6. Contribution of Ser173 regulatory site of AMPKα to cell migration/invasion. (a) C3A cells stably 
expressing either AMPKα(S173C) (S173C) or wild type AMPKα(S173) (WT) were incubated with complete 
DMEM alone (C) or in the presence of 1 mM (M1) or 5 mM (M5) metformin for 24 h. P-AMPKα(T172) and 
E-cadherin protein levels were detected in cell lysates. α Tubulin was used as loading control. Selected lanes for 
each detection are in their original order and correspond to the same gel, and they are shown after cropping, 
aligning and separating them by white space. Full-length blots are available in Supplementary Dataset. 
Immunoblots show an experiment representative of 3 independent experiments (b) C3A cells stably expressing 
either AMPKα(S173C) (S173C) or wild type AMPKα(S173) (WT) were subjected to scratch wounding (0 h) and 
incubated in complete DMEM alone (C), or in the presence of 1 mM (M1) or 5 mM metformin (M5), or 1 mM 
AICAR (AICAR), or glucose starved by incubation in no-glucose DMEM (GS) for 24 h. Data were obtained 
as indicated in Fig. 1d, and values are expressed as percentages of C. (c) S173C and WT cells were plated in 
transwell chambers as detailed in Fig. 2 and incubated with complete DMEM alone (C), or in the presence 
of 1 mM metformin (M1), or 1 mM AICAR (AICAR), or subjected to glucose starvation (GS) for 48 h, and 
processed as described in Fig. 2. Values represent the mean ± SEM of 3 experiments. *P < 0.05 vs. C. #P < 0.05 
vs. WT.
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abrogated in AMPKα silenced cells. Thus, these results supported that, by activating AMPK, metformin could 
be an effective antimigratory agent in HCC cells. In addition, activation of AMPK by metformin increased cell 
differentiation and increased E-cadherin while decreasing vimentin expression in HCC cells. These findings sug-
gested that metformin induced inhibition of cell migration/invasion in HCC cells was due, at least in part, to EMT 
reversal. Similar data were found in studies performed in diverse cancer cells, from melanoma to breast cancer, 
which show that treatment with metformin or its functional analogue berberine result in significant diminution 
of cell migration and invasion via AMPK activation and EMT reduction39–42.
Second, we demonstrated that combination of metformin with glucose starvation leads to an enhanced inhibi-
tion of cell migration and invasion in both HepG2/C3A and HuH-7 cells. In previous studies, we characterized the 
role of AMPK signaling in the response of hepatic cancer cells to glucose withdrawal and demonstrated the rapid 
AMPK activation during glucose restriction and the resultant induction of both G0/G1 cell arrest and apoptotic 
death15. Now we showed that glucose restriction also acts as an antimigratory agent, per se. Furthermore, when 
cells were exposed to metformin during glucose deprivation, the antitumor effects were increased. The impact of 
glucose restriction on the migratory ability of HCC cells had not been previously characterized. Metabolic stress 
during tumor formation activates AMPK, what is proposed to act as an initial prosurvival signal43. Nevertheless, 
most findings in different tumor cells support antitumor effects of AMPK activation by energy stress (starva-
tion or 2-deoxyglucose treatment), including novel putative targets and inhibition of migration and invasion14,44. 
Further studies will be necessary to determine if one or more of these specific targets involved in migration/
invasion are responsible of metformin triggered AMPK signaling and hence inhibit migration and invasion in 
HCC cells. However, our results support that, at least in part, an intact AMPK-p53 axis is required to signal these 
inhibitions. In fact, and in accordance with previous evidence observed in normal liver under energetic stress 
which suggest p53 stabilization by AMPK phosphorylation24, we demonstrated that AMPK activation through 
metformin is associated with an increase of p53 in HCC cells, and that cells lack of p53 show no inhibition of 
migration/invasion by metformin. Similar dependence on p53 was suggested in metformin induced apoptosis in 
breast cancer cells45. Given that p53 per se can regulate EMT and migration/invasion and that p53 also interplays 
with other direct targets of AMPK implicated in migration and invasion processes in diverse cancer cells, addi-
tional approaches of analysis are required to elucidate the role of AMPK-p53 and the downstream actors involved 
in the regulation of migration and invasion in HCC cells.
More importantly, here, we demonstrated that AMPK activation either by energy stress or by the pharma-
cological action of metformin led to the inhibition of migration/invasion of HCC cells, which was related with 
metformin concentrations and, thus, with the extent of AMPK activation. Moreover, glucose deprivation turned 
HCC cells migratory and invasive properties extremely sensitive to metformin treatment. In addition, metformin 
treatment of glucose starved cells also increased apoptotic death, what was even more pronounced at a met-
formin concentration that inhibited PKA activity. In fact, under glucose deprivation, the drastic inhibition of 
PKA entailed by 5 mM metformin was associated to a major increase of AMPK activation.
Given that metformin treatment reduces PKA mediated phosphorylation of AMPKα(Ser173) and hence 
facilitates AMPK activation in hepatic cells23, we explored the possible contribution of S173 residue of AMPKα 
to the inhibition of migration/invasion elicited by AMPK activation. We found that cells harboring the 
non-phosphorylatable S173C mutation presented decreased migration and invasion efficiencies when subjected 
to AMPK activating conditions. However, in the presence of 5 mM metformin, a concentration which inhibited 
PKA, migration was decreased to a minimum irrespective of the mutation of S173. In this sense, we concluded, 
as a third main point, that S173 phosphorylation constrains AMPK activation and affects migratory functions 
in such a way that conditions which prevent its phosphorylation by PKA enhance AMPK antimigratory effects.
Results in cultured tumor cells, subjected to their usual in vitro conditions of extremely high supply of glu-
cose and growth factors, are observed with mM instead of μM metformin concentrations, which are the plas-
matic levels in patients46. However, those concentrations were unlikely to be supra pharmacological because 
metformin concentrates in tissues several folds over blood levels and bioavailability in the liver reaches 8 mM47. 
Moreover, other antitumor effects via AMPK, analyzed firstly in cultured HCC cells, were also demonstrated in 
HCC cell-xenotransplantated mice treated with metformin at pharmacological doses4,29, this supporting further 
translational hypotheses and clinical studies with metformin in HCC patients from in vitro evidence. On the 
other hand, many results encourage the use of caloric restriction or periodic fasting for cancer treatment and pre-
vention, and diverse clinical trials are now in course48. Changes in signaling kinases are proposed to mediate these 
dietary antitumor effects, and AMPK is one of the candidates which was studied in rodents but not yet in patients. 
In fact, caloric restriction decreases tumor development in a breast cancer model in mice and this is associated 
with AMPK activation in tumor, mammary gland and liver49.
Collectively, we presented evidence regarding novel mechanisms responsible for regulating the migratory 
and invasive abilities of HCC cells. We focused on conditions that enhance AMPK signaling and result in greater 
inhibition of cell migration and invasion, as AMPK sensitivity to inhibition by PKA. Due to HCC special features, 
which comprise accumulation of mutations during chronic inflammation and rapid intrahepatic metastasis, it is a 
molecular/genetically heterogeneous cancer lacking in effective treatment50,51. In this regard, metabolic or dietary 
interventions combined with drugs targeted to signaling kinases as metformin, accompanied of early detection 
can be a promising therapy for limiting the rapid metastatic course of this disease.
Methods
Cell culture. The hepatocarcinoma cells C3A (HepG2/C3A, a clonal derivative of HepG2, ATCC, Manassas, 
VA), HuH-7 (JCRB Cell Bank, Tokyo, Japan), and Hep3B (Hep 3B2.1–7, ATCC) were grown with 4.5 g/L glu-
cose DMEM or, in the case of glucose restriction experiments, with no-glucose DMEM (Gibco, Thermo Fisher 
Scientific, Waltham, MA), supplemented with 10% FBS and antibiotics. When indicated, 1,1-Dimethylbiguanide 
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Hydrochloride (1–20 mM, Metformin) (Santa Cruz Biotechnology Inc., Santa Cruz, CA), the AMPK activator 
5-Aminoimidazole-4-carboxamide ribonucleotide (1 mM, AICAR) (Cell Signaling Technology, Danvers, MA) 
or the PKA inhibitors N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride (5 µM, 
H89) (Santa Cruz Biotechnology Inc.) or Protein Kinase A inhibitor fragment 14–22, myristoylated (10 µM, PKI) 
(Sigma Chemical Co., St Louis, MO) were added.
Reduction of AMpKα expression. For reducing AMPKα1 protein expression in HCC cells, 21 nucleotide 
duplexes targeting two specific AMPKα1 sequences and scrambled control were designed and synthesized by 
Ambion SilencerTMsiRNA (Thermo Fisher Scientific) and cells were transfected, as we previously described15. 
The target sequences corresponded to AMPKα1 1842–1864: AACATTTCTGCATATTAGGCTCCTGTCTC and 
2659–2681: AAGAGCTGAGTTGCATATACTCCTGTCTC, as we previously used15. Experiments were per-
formed 24–48 h after transfection, and the specific decrease in AMPKα expression for both duplexes was con-
firmed by immunoblotting. Reductions of 70–80% of protein expression were achieved in both cell lines.
Generation of stable cell lines. pCDNA3 plasmid harboring Myc-AMPKα1(WT) and Myc-AMPKα1 
(S173C)52,53, kindly given by Dr. Dietbert Neumann (Maastricht University), were used to generate populations of 
C3A cells stably expressing WT and mutated forms of the AMPKα1 verified by detection of cMyc and AMPKα, 
as we previously described15. The stable clones obtained were grown in a medium containing 200 μg/ml Geneticin 
(Invitrogen, Thermo Fisher Scientific), in conditions otherwise similar to that of the parental cells.
Mtt assay. Cells were cultured in 96-well microplates and methylthiazolyldiphenyl-tetrazolium bromide 
(MTT, Sigma Chemical Co., St Louis, MO) was added at the indicated time, as we previously described15. After 
2 h, the metabolite produced from viable cells was dissolved in DMSO and absorbance was detected at 540 nm in a 
microplate reader (Beckman Coulter LD400). Results were expressed as percentage of absorbance in control cells.
BrdU incorporation assay. Cells were plated onto coverslips, subjected to the indicated treatments and 
then BrdU (10 mM) was added and cells were incubated for additional 3 h. After fixed in 4% paraformaldehyde 
and permeabilized with Triton X-100, cells were washed three times with PBS for 5 min and DNA was denatu-
ralized by incubating 10 seconds in 50 mM NaOH. After treatment with a blocking solution, the cells were incu-
bated with anti-BrdU antibody (B8434 Sigma Chemical Co.), washed and incubated with secondary antibody, 
washed once again and incubated with 4′,6-diamidino-2-phenylindole (DAPI, Molecular Probes) for nuclei stain-
ing. The cells were then washed and mounted for observation under a fluorescence microscope (Nikon TE200). 
Independent areas were captured and BrdU-positive nuclei were counted and expressed as percentage (a total of 
500 nuclei on average were counted).
Annexin V/propidium iodide assay. Cells were prepared for Annexin V assay (BD Biosciences, San José, 
CA), as we previously described15. In brief, after gently homogenization in the culture medium and harvest, 
100,000 cells were carefully re-suspended and externalization of phosphatidylserine and cell death was assessed 
by staining with Annexin V-FITC and PI, respectively, coupled to flow cytometric analysis (Cell Sorter BD 
FACSAria II, BD Biosciences), following the manufacturers’ instructions.
Cell cycle analysis. Cell distribution in the cell cycle was analyzed by determining the cellular DNA content 
by flow cytometry, as we previously described15. Briefly, 1 × 106 cells were fixed with cold 70% ethanol, washed 
with PBS and stained with 50 μg/ml propidium iodide (Sigma Chemical Co.) in a buffer solution (0.1% sodium 
citrate, 0.02 mg/ml RNAse, and 0.3% NP-40). Results were analyzed using WinMDi and Cylchred softwares.
Immunofluorescence confocal microscopy. Cells were grown on glass coverslips and, at the end 
of experiments, fixed and treated, as we previously described25,54. Briefly, fixed cells were permeabilized 
and blocked with 0.3% Triton X-100-1% albumin. Then they were incubated for F-actin staining with Alexa 
560-conjugated phalloidin (Molecular Probes, Eugene, OR), washed, incubated for nuclei staining with 
4′,6-diamidino-2-phenylindole (DAPI, Molecular Probes), and mounted with ProLong (Molecular Probes). 
Fluorescence was detected by using confocal microscopy (Nikon C1SiR with inverted microscope Nikon TE200). 
Serial optical sections in the z-axis were collected, and projections were obtained using ImageJ tools. Canalicular 
structures were identified and quantified, as we previously described25.
Wound healing assay. Cell monolayers were subjected to wound healing assay to measure collective cell 
migration, as we previously described55, with slight modifications. In brief, cells seeded at 3 × 106 (C3A) or 
1,5 × 106 (HuH-7) in DMEM were cultured in 6-well plates (or 24 well-plates in the case of PKI experiments). 
After 24 h, cells were wounded by dragging a 200-μl pipette tip through the monolayer, washed and subjected to 
their respective treatments. Microscopic images (Zeiss Axiovert 25) of wounds in the same field were captured 
when the wound was made (0 h) and 24 h after wounding. The length (μm) advanced by the cells of the wound 
front was assessed by using ImageJ software. For time lapse studies, cells were cultured in 35 mm dishes and 
wounds were dragged with a 20-μl pipette tip. The cells were otherwise treated as described above and sequential 
pictures from the same field over a plate thermostated at 37 °C were automatically captured every 30 min for the 
last 3 h within 24 h of treatment. The advancing of a single cell in the wound front was assessed (a line segment 
from the initial to the final centriole position) by using ImageJ software.
Invasion assay. Invasion assay was performed using a transwell chamber (Biofil, Beijing, China) with 8 μm 
pore size polyester membrane filters. The upper side was pre-coated with 250 μg/ml Matrigel (Corning, Corning, 
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NY). Cells were trypsinized and suspended in DMEM containing 1% FBS. Next, 1 × 105 cells were added to the 
upper chamber, and the lower chamber was filled with complete DMEM medium containing 10% FBS without 
any modification throughout the experiment. Cells were subjected to their respective treatments for 48 h. After 
incubating, cells that had invaded the lower chamber were fixed with methanol, stained with 1% Toluidine Blue 
in 1% borax for 5 min, and counted using an inverted microscope.
preparation of cell lysates. Whole cell lysates were prepared, as we previously described15. Briefly, cell 
monolayers were washed, scrapped and harvested by centrifugation. Pellets were incubated for 30 min in RIPA 
buffer (1% Triton X-100 (v/v), 1% sodium deoxycholate (w/v), 0.1% SDS (w/v), 20 mM Tris, pH 8, 5 mM EDTA, 
200 mM NaCl) supplemented with protease (1 mM PMSF, 10 μg/mL leupeptin (Sigma Chemical Co.)) and phos-
phatase (10 mM NaF, 2 mM Na3VO4, 100 nM calyculin A (Sigma Chemical Co.)) inhibitors, and then sonicated. 
Protein concentration was measured according to Lowry et al.56.
Immunoblotting. Total proteins were separated by electrophoresis on SDS-polyacrylamide gels57, and trans-
ferred to polyvinylidene difluoride membranes (Perkin Elmer Life Sciences, Boston, MA, USA). Membranes 
were blocked with 5% non-fat milk/0.3% Tween/PBS. In the case of phospho-ACC and ACC detections, electro-
phoreses were performed in 6–10% gels for probing in the same samples those greater proteins (phospho-ACC, 
ACC) with regular size proteins (AMPKα, p53, etc.), and the upper halves of the gels were transfer for 3 h to 
nitrocellulose membranes and blocked with 3% albumin 0.3%Tween/TBS. All the membranes were washed and 
incubated overnight with specific primary antibodies [α tubulin (T-5168 Sigma Chemical Co.); p-ACCa (Ser 78/
Ser 80)-R, ACCa (D5), p53(DO-1) (sc-30447-R, sc-137104, sc-126 Santa Cruz Biotechnology); phospho-(Ser/
Thr) PKA Substrate, AMPKα, Phospho-AMPKα (Thr172), (9621S, 2532, 2535 Cell Signaling Technology); 
vimentin (M0725 Dako, Denmark); or E-cadherin (610182 BD Biosciences)]. Membranes were probed with the 
appropriate secondary antibody. Bands were detected by chemiluminescence (Amersham Pharmacia Biotech, 
Piscataway, NJ).
statistical analysis. Data were expressed as mean ± SEM. Student t test was used for comparison between 
groups. P < 0.05 was considered statistically significant.
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